Rosíres Pereira de Andrade

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · The Lancet Oncology · 2005 · 1.6K citations

Vaccination, Vaccinology, Vaccine Development +9

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · British Journal of Cancer · 2006 · 804 citations · Full text

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

Luisa L. Villa, Kevin A. Ault, Anna R. Giuliano et al. · Vaccine · 2006 · 465 citations

Vaccination, Vaccine Development, Human Papillomavirus Vaccines +9

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

Sven‐Eric Olsson, Luisa L. Villa, Ronaldo Lúcio Rangel Costa et al. · Vaccine · 2007 · 454 citations

Vaccination, Vaccine Development, L1 Virus-like Particle +8

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial

Warner K. Huh, Elmar A. Joura, Anna R. Giuliano et al. · The Lancet · 2017 · 448 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +11